Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212352 | 0.86 | APAF1 (0.37) | APAF1HSP90AA1RAD52DNM1 | |
| SCHEMBL4306166 | 0.83 | DNM1 (0.39) | APAF1HSP90AA1RAD52DNM1 | |
| SCHEMBL28751118 | 0.77 | DNM1 (0.43) | APAF1HSP90AA1RAD52DNM1 | |
| Tetrylammonium SCHEMBL899273 | 0.73 | TSHR (0.42) | — | |
| SCHEMBL15212411 | 0.73 | APAF1 (0.50) | APAF1HSP90AA1RAD52DNM1 | |
| SCHEMBL898635 | 0.71 | APAF1 (0.37) | APAF1HSP90AA1RAD52DNM1 | |
| Water SCHEMBL1397159 | 0.71 | — | — | |
| SCHEMBL160184 | 0.71 | — | — | |
| SCHEMBL13169630 | 0.71 | — | — | |
| SCHEMBL15212350 | 0.69 | APAF1 (0.39) | APAF1HSP90AA1RAD52DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921589-B2 | Electrolyte formulations | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-8829201-B2 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2622617-A2 | ELECTROLYTE FORMULATIONS | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130180591-A1 | ELECTROLYTE FORMULATIONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20120318360-A1 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012041437-A2 | ELECTROLYTE FORMULATIONS | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011085964-A1 | ELECTROLYTE FORMULATIONS | MERCK PATENT GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120318360-A1 | Electrolyte Formulations | NHERF1, HCN4, DDT | APAF1 4563/4885HSP90AA1 4529/4885RAD52 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.